title: Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc.
abstract: OBJECTIVE
  When a peptic ulcer is treated with proton pump inhibitors (PPI), protrusion of the ulcer base is sometimes noted during ulcer healing. To clarify the incidence of ulcer base protrusion in ulcers induced by endoscopic submucosal dissection (ESD), and whether the addition of polaprezinc, a cytoprotective agent used for treatment of gastric ulcer, to the PPI regimen helps to suppress it.
  
  
  METHODS
  One hundred sixty-three patients on which ESD was performed were randomly allocated to either two groups: one treated with lansoprazole (30mg/day) and the other with lansoprazole (30mg/day) plus polaprezinc (150mg/day) for the treatment of ESD-induced ulcer. The condition of the ESD-induced ulcer was blindly assessed two months after ESD by two physicians.
  
  
  RESULTS
  Lansoprazole plus polaprezinc group showed significantly better ulcer healing (p < 0.0001) and protrusion of the ulcer base was recognized in only 1.3% (1/77), an incidence significantly lower than that in lansoprazole group (20.7%, 16/77, p = 0.0001). Polaprezinc was the only significant factor (p = 0.0001) differentiating patients who had ulcer base protrusion (n = 17) from those who did not (n = 137).
  
  
  CONCLUSIONS
  Polaprezinc prevents protrusion of the ulcer base during the healing of ESD-induced ulcer with PPI.
authors.affiliation: Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan. t-inaba@chp-kagawa.jp
authors.forename: Tomoki
authors.initials: T
authors.lastname: Inaba
authors.forename: Shigenao
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Toyokawa
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Koji
authors.initials: K
authors.lastname: Miyahara
authors.forename: Masaki
authors.initials: M
authors.lastname: Wato
authors.forename: Kozo
authors.initials: K
authors.lastname: Kawai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okada
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D002336:Carnosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019610:Cytoprotection; D004359:Drug Therapy, Combination; D005260:Female; D005753:Gastric Mucosa / Q000601:surgery*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000601:surgery*; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D014945:Wound Healing; D017967:Zinc Compounds / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D017967:Zinc Compounds; D064747:Lansoprazole; C061957:polaprezinc; D002336:Carnosine